These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27045557)

  • 1. Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).
    Mitchell WM
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):755-70. PubMed ID: 27045557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
    Strayer DR; Carter WA; Stouch BC; Stevens SR; Bateman L; Cimoch PJ; Lapp CW; Peterson DL; ; Mitchell WM
    PLoS One; 2012; 7(3):e31334. PubMed ID: 22431963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
    Strayer DR; Young D; Mitchell WM
    PLoS One; 2020; 15(10):e0240403. PubMed ID: 33119613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.
    Smith ME; Haney E; McDonagh M; Pappas M; Daeges M; Wasson N; Fu R; Nelson HD
    Ann Intern Med; 2015 Jun; 162(12):841-50. PubMed ID: 26075755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatched double-stranded RNA: polyI:polyC12U.
    Adis Editorial
    Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR3 agonists as immunotherapeutic agents.
    Nicodemus CF; Berek JS
    Immunotherapy; 2010 Mar; 2(2):137-40. PubMed ID: 20635920
    [No Abstract]   [Full Text] [Related]  

  • 7. Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome.
    Morris MC; Cooney KE; Sedghamiz H; Abreu M; Collado F; Balbin EG; Craddock TJA; Klimas NG; Broderick G; Fletcher MA
    Clin Ther; 2019 Apr; 41(4):656-674.e4. PubMed ID: 30929860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.
    Castro-Marrero J; Sáez-Francàs N; Santillo D; Alegre J
    Br J Pharmacol; 2017 Mar; 174(5):345-369. PubMed ID: 28052319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome.
    Strayer DR; Carter WA; Brodsky I; Cheney P; Peterson D; Salvato P; Thompson C; Loveless M; Shapiro DE; Elsasser W
    Clin Infect Dis; 1994 Jan; 18 Suppl 1():S88-95. PubMed ID: 8148460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.
    Overton ET; Goepfert PA; Cunningham P; Carter WA; Horvath J; Young D; Strayer DR
    Vaccine; 2014 Sep; 32(42):5490-5. PubMed ID: 25128802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant biological and toxicological species responses to TLR3 activation.
    Mitchell WM; Nicodemus CF; Carter WA; Horvath JC; Strayer DR
    Am J Pathol; 2014 Apr; 184(4):1062-1072. PubMed ID: 24486326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome.
    Suhadolnik RJ; Reichenbach NL; Hitzges P; Adelson ME; Peterson DL; Cheney P; Salvato P; Thompson C; Loveless M; Müller WE
    In Vivo; 1994; 8(4):599-604. PubMed ID: 7893988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
    Collatz A; Johnston SC; Staines DR; Marshall-Gradisnik SM
    Clin Ther; 2016 Jun; 38(6):1263-1271.e9. PubMed ID: 27229907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Induced by Repeated Forced Swimming in Mice.
    Ohba T; Domoto S; Tanaka M; Nakamura S; Shimazawa M; Hara H
    Biol Pharm Bull; 2019; 42(7):1140-1145. PubMed ID: 31257290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action.
    Corona A; Strayer D; Distinto S; Daino GL; Paulis A; Tramontano E; Mitchell WM
    Antiviral Res; 2023 Apr; 212():105554. PubMed ID: 36804324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA drug therapy acting via the 2-5A synthetase/RNase L pathway.
    Suhadolnik RJ; Reichenbach NL; Hitzges PM; Ablashi DV; Strayer DR; Carter WA
    Ann N Y Acad Sci; 1993 Jun; 685():756-7. PubMed ID: 8363281
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
    Castro-Marrero J; Segundo MJ; Lacasa M; Martinez-Martinez A; Sentañes RS; Alegre-Martin J
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allostatic overload in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
    Arroll MA
    Med Hypotheses; 2013 Sep; 81(3):506-8. PubMed ID: 23850395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians.
    Bested AC; Marshall LM
    Rev Environ Health; 2015; 30(4):223-49. PubMed ID: 26613325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.